This study reports the use of chitosan microcapsules for daunorubicin delivery via an oral route. The potential oral delivery of the daunorubicin/chitosan microcapsules was examined using an in vivo athymic nude mice xenograft model with Non-Hodgkin's lymphoma cells. Microencapsulated daunorubicin could be administered orally with tumour growth inhibition activity.
No takes yet. Share an insight, caveat, or question.
Lam et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: